Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Other Non-Current Liabilities (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Other Non-Current Liabilities for 17 consecutive years, with $204.3 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 39.69% to $204.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $204.3 million through Dec 2025, up 39.69% year-over-year, with the annual reading at $204.3 million for FY2025, 39.69% up from the prior year.
  • Other Non-Current Liabilities hit $204.3 million in Q4 2025 for Integra Lifesciences Holdings, down from $233.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $253.2 million in Q2 2025 to a low of $32.6 million in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $148.0 million across 5 years, with a median of $149.8 million in 2023.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 72.89% in 2022 and later soared 513.31% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $120.3 million in 2021, then tumbled by 72.89% to $32.6 million in 2022, then skyrocketed by 513.31% to $199.9 million in 2023, then decreased by 26.86% to $146.2 million in 2024, then skyrocketed by 39.69% to $204.3 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for IART at $204.3 million in Q4 2025, $233.3 million in Q3 2025, and $253.2 million in Q2 2025.